Application of SND1 in preparation of medicine for preventing and treating ischemia caused by vascular injury

A technology for vascular injury and drugs, which is applied in the field of preparation of drugs for the prevention and treatment of vascular injury and ischemia, can solve the problems that the effect has not yet been studied, and achieve the effect of improving vascular ischemia

Active Publication Date: 2021-06-11
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing studies have shown that SND1 has nucleic acid binding and transcription coordination activity, but its role in vascular ischemia-related diseases such as limb ischemia has not yet been studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of SND1 in preparation of medicine for preventing and treating ischemia caused by vascular injury
  • Application of SND1 in preparation of medicine for preventing and treating ischemia caused by vascular injury
  • Application of SND1 in preparation of medicine for preventing and treating ischemia caused by vascular injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] All animal experiments were performed according to standard procedures and were approved by the Animal Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Lower limb ischemia was performed on the left lower limb of the mice. The recovery of ischemic perfusion in lower limbs of mice was detected by Doppler flowmeter.

[0052] figure 1 Middle A is an 8-week-old male C57BL / 6 mouse, which was given control (Ad-GFP) and SND1-overexpressing adenovirus (Ad-SND1), respectively, and intramuscularly injected into both lower limbs once a day, and lower limb ischemia was performed on the left lower limb of the mouse . Before operation, on the first day after operation, on the third day after operation, on the seventh day after operation, and on the fourteenth day after operation, Doppler flowmeter was used to detect the recovery of ischemic perfusion in the lower limbs of mice. figure 1 Middle B is the relative value of perfusion recovery o...

Embodiment 2

[0057] 8-week-old male C57BL / 6 mice underwent left lower limb ischemia surgery. The mice were sacrificed on the first day, third day, seventh day, and fourteenth day after the operation, and the protein was extracted from the tissue of the surgical site. Protein expression levels were detected by western blotting.

[0058] figure 2 Middle A is the protein electrophoresis image, the first row is the expression of SND1 protein, and the second row is the expression of Tubulin protein; lanes 1-4 are the first day, third day, seventh day, and tenth day of the sham operation group (Non-HLI). The protein of lower limb tissue after four days, lanes 5-8 are the protein of lower limb tissue after the first day, the third day, the seventh day and the fourteenth day of the lower limb ischemia operation group (HLI), respectively.

[0059] Depend on figure 2 In A, it can be seen that the protein level of SND1 in the lower limb ischemia operation group was significantly higher than that ...

Embodiment 3

[0063] After HUVEC cells were treated with siRNA knockdown control, siRNA knockdown SND1, adenovirus control and adenovirus overexpression SND1, the proliferation of HUVEC was detected by EdU assay.

[0064] image 3 Middle A is the siRNA knockdown control group (control group) and the siRNA knockdown SND1 treatment group (siSND1) using EdU assay to detect the proliferation of human umbilical vein endothelial cells (HUVEC). The first column is DAPI-stained nuclei, the second column is EdU-stained nuclei, and the third column is the fusion map (Merge) of the first two columns; the first row is the siRNA knockdown control group (control group), and the second row is the siRNA knockdown group. Low SND1 treatment group (siSND1).

[0065] image 3 Middle B is the statistical graph of HUVEC proliferation detected by EdU assay in siRNA knockdown control group (control group) and siRNA knockdown SND1 treatment group (siSND1).

[0066] Depend on image 3 In A and B, it can be seen ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of SND1 in preparation of a medicine for preventing and treating ischemia caused by vascular injury. The SND1 can promote proliferation, migration and tube formation of endothelial mother cells, so that angiogenesis is promoted, and vascular diseases, including lower limb ischemia, caused by ischemia are prevented and / or treated.

Description

technical field [0001] The present invention relates to the application of SND1, in particular to the application of SND1 in the preparation of drugs for preventing and treating blood vessel injury and ischemia. Background technique [0002] Staphylococcal Nuclease Domain-Containing Protein (SND1, Staphylococcal Nuclease And Tudor Domain Containing 1), also known as Staphylococcal Nuclease Domain-Containing Protein 1; EBNA2 Coactivator P100; Tudor Domain-Containing Protein 11, contains 910 amino acids, and its molecular weight is 101997Da. NCBI reference sequence number: NP_055205.2, the amino acid sequence is as follows: [0003] MASSAQSGGSSGGPAVPTVQRGIIKMVLSGCAIIVRGQPRGGPPPERQINLSNIRAGNLARRAAATQPDAKDTPDEPWAFPAREFLRKKLIGKEVCFTIENKTPQGREYGMIYLGKDTNGENIAESLVAEGLATRREGMRANNPEQNRLSECEEQAKAAKKGMWSEGNGSHTIRDLKYTIENPRHFVDSHHQKPVNAIIEHVRDGSVVRALLLPDYYLVTVMLSGIKCPTFRREADGSETPEPFAAEAKFFTESRLLQRDVQIILESCHNQNILGTILHPNGNITELLLKEGFARCVDWSIAVYTRGAEKLRAAERFAKERRLRIWRDYVAPTANLDQKDKQFVAKVMQV...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P9/10
CPCA61K38/164A61P9/10
Inventor 黄恺陈敏胡霁梁明露
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap